Amphastar Pharma (AMPH) Stock Forecast & Price Target

Amphastar Pharma is downgraded to a Hold due to expected top-line growth concerns and lack of near-term catalysts, as evidenced by Baqsimi's significant underperformance, leading to a downward revision of expected 2026 growth and a recent 3% price increase in May. While the company has taken steps to address these issues, pricing may still not return to prior levels, resulting in a flat-to-low single digit growth for Baqsimi, and the lack of new products and ANDA approvals until 2027.

Amphastar Pharma is facing several challenges that have led to a negative outlook, including troubles with pricing for their product Baqsimi due to higher rebates and discounts, as well as competitive pressure in the generics market. Additionally, the company heavily relies on the success of its pipeline and has significant ownership from two directors, making them influential in corporate decisions. Despite maintaining expectations for overall top-line growth, the recent launch of ipratropium bromide HFA has not seen significant competition. This, combined with the uncertainty of pipeline success and price pressures, leads to a lack of visibility in top-line and EBITDA growth and a fairly valued stock at an EV/2027E EBITDA of ~7x.